Forte Biosciences IncNASDAQ:FBRX
- LAST PRICE5.8400
- TODAY'S CHANGE (%)0.2600 (4.6595%)
- Bid / Lots5.4000/ 1
- Ask / Lots6.2000/ 1
- Open / Previous Close5.6500 / 5.5800
- Day Range
- 52 Week Range
- Volume11,205
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBRX |
|---|---|---|
| 09:32 ET | 320 | 5.65 |
| 09:33 ET | 1000 | 5.6 |
| 09:37 ET | 1000 | 5.45 |
| 09:42 ET | 300 | 5.5842 |
| 10:00 ET | 268 | 5.5771 |
| 10:02 ET | 200 | 5.55 |
| 10:09 ET | 100 | 5.525 |
| 10:20 ET | 200 | 5.57 |
| 10:26 ET | 1900 | 5.58 |
| 10:45 ET | 100 | 5.6 |
| 11:03 ET | 100 | 5.6 |
| 11:12 ET | 100 | 5.6 |
| 11:25 ET | 100 | 5.6 |
| 11:48 ET | 100 | 5.59 |
| 11:59 ET | 100 | 5.59 |
| 12:24 ET | 100 | 5.58 |
| 12:42 ET | 100 | 5.57 |
| 01:26 ET | 100 | 5.6 |
| 01:40 ET | 100 | 5.6 |
| 02:27 ET | 200 | 5.6 |
| 02:39 ET | 200 | 5.6 |
| 03:15 ET | 924 | 5.63 |
| 03:17 ET | 143 | 5.55 |
| 03:32 ET | 100 | 5.84 |
Yesterday
DJ Forte Biosciences Is Maintained at Buy by Chardan Capital, from 16 hours ago by Dow Jones
16 hours ago by Dow Jones
Nov 14, 2024
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow Jones*DJ Forte Biosciences 3Q Loss/Shr $4.54 >FBRX, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Forte Biosciences Inc | 8.5M | -0.3x | --- |
Mustang Bio Inc | 8.5M | -0.1x | --- |
Conduit Pharmaceuticals Inc | 8.6M | -1.3x | --- |
Galecto Inc | 8.4M | -0.3x | --- |
Vincerx Pharma Inc | 8.8M | -0.2x | --- |
Bioxytran Inc | 7.9M | -4.9x | --- |
Company Information
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Contact Information
- Headquarters
- 3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS, TX, United States 75247
- Phone
- 310-618-6994
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Paul Wagner
- Chief Financial Officer
- Antony Riley
- Independent Director
- Scott Brun
- Independent Director
- Stephen Doberstein
- Independent Director
- Barbara Finck
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.08 |
EPS | $-20.00 |
Book Value | $24.30 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
